ERBB2 and glioblastoma: (87) reported an open-label phase I dose-escalation trial, which demonstrated that the infusion of autologous HER2-specific CAR-modified virus-specific T cells (HER2-CAR VSTs) is safe and may be associated with clinical benefit in progressive GBM patients.